nurulimab

Home
Ligands
nurulimab

GtoPdb Ligand ID: 12992

Synonyms: BCD-145 | BCD145

Comment: Nurulimab (BCD-145) is a human IgG1 anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) monoclonal antibody. It blocks the interaction between CTLA4 and its ligands CD80 and CD86, which establishes an inhibitory immune checkpoint. Blocking this checkpoint offers therapeutic potential as this mechanism stimulates the immune system to destroy cancer cells.

Summary
Biological activity
Clinical data
References
Immunopharmacology

References
1. Korman AJ, Halk EL, Lonberg NL, Deo YM, Keler TP. (2006) Human CTLA-4 antibodies. Patent number: US6984720B1. Assignee: Medarex LLC. Priority date: 24/08/2000. Publication date: 10/01/2006.

References

1. Korman AJ, Halk EL, Lonberg NL, Deo YM, Keler TP. (2006)
Human CTLA-4 antibodies.
Patent number: US6984720B1. Assignee: Medarex LLC. Priority date: 24/08/2000. Publication date: 10/01/2006.